Search Within

Tiffany Troso-Sandoval

Formats
  1. Meeting Abstract (27)
  2. Journal Article (22)
Groups
  1. Department of Medicine (49)
  2. GDMT, Medicine (49)
  3. Gynecologic Medicine Service (49)
  4. Gynecology Disease Management Team (49)
  5. Solid Tumor Oncology Division (49)
  6. Epidemiology and Biostatistics (34)

More Groups

People
  1. Clifford Hudis (22)
  2. Larry Norton (20)
  3. Diana Lake (19)
  4. Monica Fornier (18)
  5. Steven Sugarman (17)
  6. Chau Dang (16)

More People

Years
  1. 2025 (1)
  2. 2024 (3)
  3. 2023 (3)
  4. 2022 (5)
  5. 2021 (3)
  6. 2020 (4)

More Years

Publications
  1. Journal of Clinical Oncology (16)
  2. Breast Cancer Research and Treatment (7)
  3. Cancer Research (5)
  4. Annals of Oncology (4)
  5. Clinical Cancer Research (4)
  6. Clinical Breast Cancer (3)

More Publications

Publishers
  1. American Society of Clinical Oncology (16)
  2. American Association for Cancer Research (9)
  3. Springer (7)
  4. Elsevier Inc. (6)
  5. Oxford University Press (4)
  6. American Medical Association (1)

More Publishers

Results (49)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase II study of fulvestrant plus abemaciclib in hormone receptor–positive advanced or recurrent endometrial cancer
    Journal Article

    Green, A. K.; Zhou, Q.; Iasonos, A.; Zammarrelli, W. A. 3rd; Weigelt, B.; Ellenson, L. H.; Chhetri-Long, R.; Shah, P.; Loh, J.; Hom, V.; more...
    Clinical Cancer Research (2025)

    Fulltext@MSK | Save
  • A phase II study of fulvestrant and abemaciclib in hormone receptor positive advanced or recurrent endometrial cancer
    Meeting Abstract

    Green, A.; Zhou, Q.; Iasonos, A.; Zammarrelli, W.; Weigelt, B.; Ellenson, L. H.; Chhetri-Long, R.; Shah, P.; Hom, V.; Erinjeri, J. P.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Nivolumab for mismatch-repair-deficient or hypermutated gynecologic cancers: A phase 2 trial with biomarker analyses
    Journal Article

    Friedman, C. F.; Manning-Geist, B. L.; Zhou, Q.; Soumerai, T.; Holland, A.; Da Cruz Paula, A.; Green, H.; Ozsoy, M. A.; Iasonos, A.; Hollmann, T.; more...
    Nature Medicine (2024)

    Fulltext@MSK | Save
  • A phase 2 trial of zanidatamab in HER2-overexpressed advanced endometrial carcinoma and carcinosarcoma (ZW25-IST-2)
    Journal Article

    Lumish, M.; Chui, M. H.; Zhou, Q.; Iasonos, A.; Sarasohn, D.; Cohen, S.; Friedman, C.; Grisham, R.; Konner, J.; Kyi, C.; more...
    Gynecologic Oncology (2024)

    Fulltext@MSK | Save
  • HER2 genetic intratumor heterogeneity is associated with resistance to trastuzumab and trastuzumab emtansine therapy in recurrent high-grade endometrial cancer
    Journal Article

    Shen, S.; Ma, W.; Brown, D.; Da Cruz Paula, A.; Zhou, Q.; Iaosonos, A.; Tessier-Cloutier, B.; Ross, D. S.; Troso-Sandoval, T.; Reis-Filho, J. S.; more...
    Modern Pathology (2023)

    Fulltext@MSK | Save
  • Morbidity after secondary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for ovarian cancer: An analysis of a randomized phase II trial
    Journal Article

    Praiss, A. M.; Zhou, Q.; Iasonos, A.; Moukarzel, L.; Dessources, K.; Soldan, K.; Su, K.; Sonoda, Y.; Roche, K. L.; Gardner, G. J.; more...
    Gynecologic Oncology (2023)

    Fulltext@MSK | Save
  • Durvalumab with or without tremelimumab in patients with persistent or recurrent endometrial cancer or endometrial carcinosarcoma: A randomized open-label phase 2 study
    Journal Article

    Rubinstein, M. M.; Doria, E. R.; Konner, J.; Lichtman, S.; Zhou, Q.; Iasonos, A.; Sarasohn, D.; Troso-Sandoval, T.; Friedman, C.; O'Cearbhaill, R.; more...
    Gynecologic Oncology (2023)

    Fulltext@MSK | Save
  • A phase II trial of IDO-inhibitor, BMS-986205 (IDO), and PD-1 inhibitor, nivolumab (NIVO), in recurrent or persistent endometrial cancer (EC; CA017-056)
    Meeting Abstract

    Kyi, C.; Rubinstein, M. M.; Shah, P.; Zhou, Q.; Iasonos, A.; Liu, Y.; Ramirez, L.; Paroder, V.; Green, A.; Friedman, C. F.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Dysfunctional CD8+T cells in the tumor microenvironment are associated with response to nivolumab in mismatch repair deficient (dMMR) or hypermutated ovarian (OVCA) or endometrial cancer (EC)
    Meeting Abstract

    Friedman, C. F.; Zhou, Q.; Iasonos, A.; Holland, A.; Ramirez, L.; Grisham, R. N.; Guo, R.; Lichtman, S. M.; Kyi, C.; Makker, V.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Adjuvant enzalutamide for the treatment of early-stage androgen-receptor positive, triple negative breast cancer: A feasibility study
    Meeting Abstract

    Walsh, E. M.; Gucalp, A.; Patil, S.; Edelweiss, M.; Ross, D. S.; Razavi, P.; Modi, S.; Iyengar, N. M.; Sanford, R.; Troso-Sandoval, T.; more...
    Cancer Research (2022)

    Fulltext@MSK | Save